drugset / Trial / NCT06669533
Use Misoprostol to Optimize Prevention of Cervical Cancer
Recruiting
420 enrolled
University of Alabama at Birmingham
Cameroon Baptist Convention Health · collab
RandomizedSingle-groupOpen-labelScreening
Summary
This is a double-blind randomized controlled trial of 420 non-pregnant women undergoing cancer screening by visual inspection with acetic acid (VIA) who have Type 3 transformation zone (TZ) and randomized to receive either Misoprostol or placebo.
Timeline
- Start
- 2025-02-25
- Primary completion
- 2026-11-04
- Completion
- 2027-11-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Misoprostol | Other / unclassified | 600 ug | Other |